Linerixibat

利奈昔巴特

Report date: 2026/03/26 09:36:27
NME

Base Information

Drug NameLinerixibat
Drug Alias NameGSK-672GSK-2330672
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIleal bile acid transporter inhibitors
TargetsIleal bile acid transporter
Therapy Area/IndicationsDiabetes Mellitus, Type 2PruritusCholangitis, Sclerosing +[5] 
Global Approved IndicationsCholangitis, Sclerosing
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2026/03/17
Country/TerritoryCzechiaBelgiumBulgaria +[20] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Trading Services LtdGlaxosmithkline PlcGlaxosmithkline (Ireland) Ltd +[8] 
Inactive CompaniesN/A
Active IndicationsPruritusCholangitis, SclerosingCholestasis
Inactive IndicationsDiabetes Mellitus, Type 2Cholestasis, Intrahepatic

Other Information

ATC CodeN/A
Related LinksN/A